Cizzle Bio has confirmed that its CIZ1B lung cancer biomarker blood test is available through licensed healthcare providers in the San Antonio metropolitan area, expanding its US commercial coverage.
The test analyses a blood sample for a specific variant of the CIZ1 protein associated with lung cancer. It is designed to provide additional information to healthcare professionals when assessing patients for potential lung cancer.
The company is targeting patients with relevant risk factors, symptoms or previous imaging findings. These may include smoking history, family history of lung cancer and exposure to environmental or occupational risks.
The CIZ1B test is intended to complement existing screening and diagnostic procedures, including low-dose computed tomography (LDCT). It does not replace imaging, biopsies or specialist medical assessments.
Healthcare providers determine whether testing is appropriate and interpret the results alongside a patient’s medical history and other clinical information.
The San Antonio launch extends Cizzle Bio’s existing availability in the Dallas-Fort Worth metropolitan area, giving the company access to another major US healthcare market.
The expansion forms part of its efforts to increase access to CIZ1B testing and establish relationships with healthcare providers as it develops the commercial potential of its lung cancer biomarker technology.
Cizzle Biotechnology Holdings plc (LON:CIZ) is a pioneering cancer diagnostics company, originally a spin-out from the University of York, and now listed on the London Stock Exchange.
